Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece

CAMBRIDGE, MA--(Marketwired - Jul 16, 2013) - Arch Therapeutics, Inc. ( OTCQB : ARTH ) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a keynote lecture titled "Translating Nanomedicine: Molecular medical devices from Nano Neuro Knitting to Immediate Hemostasis to Cancer Stem Cell Arrest" in Corfu, Greece at the Technology Transfer Workshop: From the Lab to the Marketplace.

Dr. Ellis-Behnke was instrumental in discovering the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care faster and safer through the development and proposed commercialization of the Company's flagship product candidate known as AC5™. The product is based on a self-assembling peptide solution that creates a physical, mechanical barrier, which could be applied to bleeding organs or wounds to seal leaking blood and other fluids.

Dr. Ellis-Behnke presented during a day-long special workshop, addressing nanotechnology transfer, which was part of a larger four-day conference, the 4th International Conference for Nanoparticles and Nanomaterials to Nanodevices and Nanosystems, which reviewed the current state-of-the-art in nanoscience and nanotechnology, and identifies challenging and rewarding research directions.

Ellis-Behnke talked about his discovery of new molecular medical devices and how they will change medicine and the entire healthcare system. "Controlling the healing process is critical for the recovery of any injury, especially burn trauma," Ellis-Behnke continues, "First a barrier must be created to stop bleeding. In a surgical setting, we've shown that we can stop bleeding in small and large animals in less than 15 seconds, in multiple tissues, as well as a variety of different wounds, using a self-assembling peptide that creates a barrier and incorporates it into the surrounding tissue to form an extracellular matrix. This is all achieved without clotting and we've found that it does not induce an immune response."

An added benefit of the nanomaterial is that it is optically transparent. "Placing it on a wound not only stops the bleeding quickly and creates a barrier; it also provides a clear view of the surgical field while operating through it."

"This technology will impact the operating room in a fundamental way through the reduction in procedure time, along with the ability to control the environment so operations can be performed in less than optimal conditions while maintaining surgical field integrity," said Ellis-Behnke. "The time to perform an operation could potentially be reduced by up to 50 percent."

Additional details regarding Arch Therapeutics, Inc., its business, agreements and related matters are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission ("SEC"), and are available at the SEC's website at www.sec.gov . For more information, visit our website at www.archtherapeutics.com .

About Arch Therapeutics, Inc. ( OTCQB : ARTH ) Arch Therapeutics, Inc. ( OTCQB : ARTH ) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch's goal is to develop and commercialize products based on our innovative technology platform that make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate known as AC5™ is being designed to elegantly achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com .

Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov .

On Behalf of the Board,

Terrence W. Norchi, MD. Arch Therapeutics, Inc.

Contact: ARTH Investor Relations Toll Free: +1-855-340-ARTH (2784) (US and Canada) Email: investors@archtherapeutics.com Website: www.archtherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 131

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 199

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 112

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
UnitedHealth’s CMS Audit Shock Puts Disclosures Under Lens

Updated Category News Views 98

Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 46

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 84

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 111

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Geothermal AI Nodes Take Aim at Stranded Well Power

Updated Category News Views 175

Millions of idle wells are sitting under America like unwanted basement clutter, and GEIOS GEOFLEX thinks some can become small, self-contained AI power plants. That is the provocative idea behind its Dark Token Factory partnership with Aiden Digital Labs: bolt an autonomous compute module onto an abandoned or non-producing oil and gas well, pull geothermal heat from...

Continue Reading

Top 5 Most Recently Viewed Articles

Italian Stock Market Trends: Key Performers and Insights

Updated Category News Views 285

Italian Stock Market Trends and Performance In recent trading sessions, stocks across Italy have shown a positive trend as various sectors drive the market higher. Milestones were achieved as gains in the telecommunications, industrials, and utilities sectors helped push shares up, reflecting investor confidence. One of the notable indices, the Investing.com Italy 40, saw...

Continue Reading
Investor Notice: AppLovin Corporation Faces Investigation

Updated Category News Views 443

Investigation Launched into AppLovin Corporation Recent activities surrounding AppLovin Corporation (NASDAQ: APP) have caught the attention of legal experts. The law firm Robbins Geller Rudman & Dowd LLP is currently dissecting possible violations of U.S. federal securities laws involving the company. The focus of this investigation is on whether AppLovin and its...

Continue Reading
Understanding the 1H 2025 Cybersecurity Landscape and Trends

Updated Category News Views 293

Analyzing 1H 2025 Cybersecurity Trends and Threats In the ever-evolving world of cybersecurity, recent analyses indicate a concerning rise in sophisticated identity attacks. The 1H 2025 Threat Intelligence Report published by Ontinue sheds light on various notable cybersecurity trends observed in the first half of the year. This report emphasizes the increasing...

Continue Reading
Key Disclosure of Rathbones Group Plc's Interest in Balanced Commercial Property Trust

Updated Category News Views 69

In the realm of finance, transparency isn't just a nice-to-have; it's essential. Rathbones Group Plc got it right back then when they disclosed their stake in Balanced Commercial Property Trust Limited, holding a hefty 20,466,159 shares—about 2.91% of the total shareholding. You know how traders can get jumpy about these disclosures, and this one was no exception....

Continue Reading
Navigating Market Volatility with Amazon.com Inc. Strategies

Updated Category News Views 130

Understanding Market Volatility The financial markets are currently experiencing pronounced volatility, marked by recent days of significant declines. This scenario presents a unique opportunity for investors who are keen to capitalize on potential gains, especially through strategic trading methods. Double Butterfly Strategy Explained One effective trading approach...

Continue Reading